Highlights
1 patent
About
Cell Therapy for Modulating Excitable Tissues
GeneGrafts Ltd is a biotechnology company developing proprietary technology for modulating excitable tissues, such as of the brain or heart, by cell therapy. This new paradigm can be used for treatment of various diseases including Parkinson's disease and other neurological disorders or cardiac arrhythmias. Thetechnology platform is based on transplantation of cell grafts, isolated from the patient's own body, which defines the ion channels. These grafted cells integrate functionally and structurally with the target organ, and their electrical properties are derived from the expressed ion channels. The electrical properties of the target organ are modulated in a predetermined way.
Identity
| Name | GeneGrafts |
|---|---|
| Slug | genegrafts |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6_0qcKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Nov 2018 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Haifa |
| HQ address | Binyamin Disraeli Street 57, Haifa, Israel |
Web & social
| https://www.linkedin.com/company/genegrafts-ltd |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyHealthcareProviders
Business models
B2B
Tags
cardiologyparkinsonbiotechnologymedical-technologieshospitalsneurologycell-therapy
Funding
| Total raised | $800K |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}